Navigation Links
New NIAID grants strengthen national biodefense and emerging infectious diseases research network

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four-year grants totaling approximately $80 million for two new Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). The grants to the University of California, Irvine, and Colorado State University (Fort Collins) mark the completion of a national network of academic centers that conducts research to counter threats from bioterror agents and emerging infectious diseases. Each institution will receive approximately $10 million per year for the next four years to head a regional research consortium. The RCE network was identified as a national priority in the 2002 NIAID Biodefense Research Agenda.

"Since before the 2001 anthrax attacks, the United States has been at risk for a bioterror attack. With these grants, a key element of our strategic plan to counter bioterrorism and emerging infectious diseases is now complete," says Anthony S. Fauci, M.D., director of NIAID. "Our network is working diligently to uncover new knowledge and create preventive, therapeutic and diagnostic tools that will leave us far less vulnerable."

NIAID established the RCE network in 2003 with grants to eight institutions. Each institution also leads an RCE consortium made up of universities and other research institutions within its geographic region. The network conducts research that will lead to next-generation treatments, vaccines and diagnostic tools for diseases such as anthrax, plague, smallpox, tularemia, botulism and West Nile fever.

University of California, Irvine, principal investigator Alan G. Barbour, M.D., will head a consortium whose members include four additional University of California campuses and 11 other regional universities and research institutions.

Colorado State University principal investigator Barry J. Beaty, Ph.D., will head a consortium whose members include five o ther universities plus small business partners; it also includes substantial collaboration with the Centers for Disease Control and Prevention.

The addition of these two new RCEs expands the network's scientific reach to cover some poorly understood diseases and new research needs. For example, researchers in the new centers have expertise in equine encephalitis and other viral diseases that can be transmitted to people by mosquitoes. The centers also add expertise in hantaviruses, as well as in the development of diagnostics and animal models of disease.

Each consortium within the network will

* support investigator-directed research
* train researchers and other personnel for biodefense research activities
* create and maintain supporting resources, including scientific equipment and trained support personnel, for use by other researchers within in the region and network
* emphasize research focused on development and testing of vaccines, therapeutic and diagnostic concepts
* make available core facilities to approved investigators from academia, government, biotech companies and the pharmaceutical industry
* provide facilities and scientific support to first responders in the event of a national biodefense emergency

The previously established RCEs in the network are led by Duke University, Harvard Medical School, New York State Department of Health, University of Chicago, University of Maryland, University of Texas Medical Branch (Galveston), University of Washington and Washington University in St. Louis. Additional information on NIAID's biodefense program is available online at http://www.niaid.nih.gov/Biodefense/Research/rce.htm.


'"/>

Source:NIH


Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. NIAID begins clinical trial of West Nile virus vaccine
3. NIAID researchers show how promising TB drug works
4. NIAID DNA vaccine for H5N1 avian influenza enters human trial
5. NIAID expands capability for influenza research and surveillance
6. Asian immigrants in NYC not receiving HIV education at religious institutions
7. Scientists win grants to develop $1,000 genome sequencing technology
8. UCLA scientists strengthen case for life more than 3.8 billion years ago
9. Brain networks strengthened by closing ion channels
10. International trial of two microbicides begins
11. International HapMap consortium expands mapping effort
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Switzerland from December 5-10. ... Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... to their offering. ... , An increasing ... anticipated. Nanotechnology will be applied at all stages of drug ... in clinical trials. Many of the assays based on nanobiotechnology ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
Breaking Biology Technology: